Document:

FORM OF SERIES C WARRANT

 Exhibit 4.3 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE
SECURITIES LAWS. THIS WARRANT AND SUCH UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. 

OBALON THERAPEUTICS, INC. 

PREFERRED STOCK PURCHASE WARRANT 

This Preferred Stock Purchase Warrant (the “Warrant”) is issued as of February 24, 2012, by Obalon Therapeutics,
Inc., a Delaware corporation (the “Company”), to [            ], or its assigns (the “Holder”). This Warrant is one of a series of Warrants
containing substantially identical terms and conditions issued by the Company pursuant to the Note and Warrant Purchase Agreement dated as of February 24, 2012 by and among the Company and the purchasers described therein (the
“Purchase Agreement”) with an aggregate principal amount of $1,500,000.00 (the “Notes”). Capitalized terms used but not defined herein shall have the meaning therefor set forth in the Purchase
Agreement or the Notes, as applicable. This Warrant is subject to the following terms and conditions. 
 1. Issuance of Warrant;
Number of Shares; Term; Price 
 1.1. Issuance. The Company, for value received, hereby certifies that the Holder is
entitled, subject to the terms set forth below, to purchase from the Company, after the first to occur of the events specified in Section 1.1 (a) or (b) below but on or before the Expiration Date (as defined in Section 1.2
below) the following number of Shares of the Company at the following exercise price: 
 (a) If the Notes automatically convert into shares
of the securities sold in a Next Equity Financing as provided under the Notes, then, concurrently therewith, this Warrant shall be and shall be deemed to be exercisable (i) for a number of shares of the securities sold in the Next Equity
Financing equal to 10% of the original principal amount of the Holder’s Note divided by the price at which such securities are sold in the Next Equity Financing, and (ii) at an exercise price equal to the price at which such securities are
sold in the Next Equity Financing. 
 (b) In the event that (i) a Next Equity Financing does not occur prior to the earlier of
(A) the first closing of a transaction that results in a Change of Control or (B) the Maturity Date, then this Warrant shall be and shall be deemed to be exercisable (Y) for a number of shares of the Series B Preferred Stock equal to
10% of the original principal amount of the Holder’s Note divided by the conversion price for the Series B Preferred Stock as in effect as of the date immediately preceding the date of the first closing of such Change of Control

 
transaction, the Maturity Date, or the date upon which the Notes are converted into Series B Preferred Stock, as applicable, and (Z) at an exercise price equal to such conversion price for
the Series 8 Preferred Stock. 
 1.2. Definitions. For purposes of this Warrant, the following terms shall have the following
meanings: 
 (a) “Shares” shall mean the shares of Warrant Stock issuable upon exercise of this Warrant. 

(b) “Warrant Stock” shall mean the securities for which this Warrant may be exercisable from time to time. 

1.3. Term. This Warrant shall be exercisable upon the terms herein set forth until the date that is seven (7) years from
the issue date of this Warrant referenced above (the “Expiration Date”). 
 1.4. Notice. In case
(a) the Company shall take a record of the holders of its Common Stock or Series B Preferred Stock (or other stock or securities at the time deliverable upon the exercise of this Warrant) for the purpose of entitling or enabling them to receive
any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right, to subscribe for or purchase any shares of stock of any class or any
other securities, or to receive any other right, or (b) of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation or merger of the Company, any consolidation or merger of the
Company with or into another corporation (other than a consolidation or merger in which the Company is the surviving entity), or any transfer of all or substantially all of the assets of the Company, including without limitation, any Change of
Control, or (c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Company, then, and in each such case, the Company will mail or cause to be mailed to the Holder a notice specifying, as the case may be, (i) the
date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization,
reclassification, consolidation, merger, transfer, Change of Control transaction, dissolution, liquidation, winding-up, redemption or conversion is to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock
or Series 8 Preferred Stock (or such other stock or securities at the time deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up, redemption or conversion) are to be determined.
Such notice shall be mailed to the Holder at least ten (10) days prior to the record date or effective date for the event specified in such notice. 

1.5. Exercise Price. Subject to adjustment as hereinafter provided, the price per share for which all or any of the Shares may
be purchased pursuant to the terms of this Warrant shall be equal to the exercise price determined in accordance with Section 1.1(a) or 1.1(b), as applicable (the “Exercise Price”). 

  
 2 

 2. No Fractional Shares. No fractional shares of Warrant Stock will be issued in
connection with any subscription hereunder. In lieu of any fractional shares that would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the fair market value of one share of Warrant Stock on the
date of exercise, as determined in good faith by the Company’s Board of Directors. 
 3. No Shareholder Rights. This
Warrant as such shall not entitle its holder to any of the rights of a stockholder of the Company until the holder has exercised this Warrant in accordance with Section 4 or Section 5 hereof. 

4. Exercise of Warrant. This Warrant may be exercised by the Holder by the surrender of this Warrant at the principal office of
the Company, accompanied by payment in full of the purchase price of the shares purchased thereby, as described above. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its surrender for
exercise as provided above, and the person or entity entitled to receive the shares or other securities issuable upon such exercise shall be treated for all purposes as the holder of such shares of record as of the close of business on such date. As
promptly as practicable, the Company shall issue and deliver to the person or entity entitled to receive the same a certificate or certificates for the number of full shares of Warrant Stock issuable upon such exercise, together with cash in lieu of
any fraction of a share as provided above. The shares of Warrant Stock issuable upon exercise hereof shall, upon their issuance, be fully paid and nonassessable. If this Warrant shall be exercised in part only, the Company shall, at the time of
delivery of the certificate representing the Shares or other securities in respect of which this Warrant has been exercised, deliver to the Holder a new Warrant evidencing the right to purchase the remaining Shares or other securities purchasable
under this Warrant, which new warrant shall, in all other respects, be identical to this Warrant. 
 5. Net Issue Election.

 5.1. Right to Convert. In addition to and without limiting the rights of the Holder under the terms of this Warrant, the
Holder shall have the right to convert this Warrant or any portion hereof (the “Conversion Right”) into shares of Warrant Stock as provided in this Section 5. Upon exercise of the Conversion Right with respect to
a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the Holder (without payment by the Holder of any cash or other consideration) that number of shares of
Warrant Stock equal to the quotient obtained by dividing (x) the value of this Warrant (or the specified portion hereof) on the Conversion Date (as defined in subsection 5.2 hereof), which value shall be determined by subtracting
(A) the aggregate Exercise Price of the Converted Warrant Shares immediately prior to the exercise of the Conversion Right from (B) the aggregate fair market value of the Converted Warrant Shares issuable upon exercise of this Warrant (or
the specified portion hereof) on the Conversion Date (as herein defined) by (y) the fair market value of one share if Warrant Stock on the Conversion Date (as herein defined). No fractional shares shall be issuable upon exercise of the
Conversion Right, and if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the Holder an amount in cash equal to the fair market value of the resulting
fractional share on the Conversion Date. 

  
 3 

 5.2. Method of Exercise. The Conversion Right may be exercised by the Holder by the
surrender of this Warrant at the principal office of the Company together with a written statement specifying that the Holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant that are being
surrendered (referred to in subsection 5.1 hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon such surrender of this Warrant (the “Conversion Date”).
Certificates for the shares of Warrant Stock issuable upon exercise of the Conversion Right shall be issued as of the Conversion Date and shall be delivered to the Holder immediately following the Conversion Date, or, if requested at the time of
surrender of this Warrant, held for pick-up by the Holder at the Company’s principal office. 
 5.3. Determination of Fair Market
Value. For purposes of this Section 5, fair market value (the “Market Price”) of a share of Warrant Stock as of a particular date (the “Determination Date”) shall mean, where such
security is listed on a security exchange at the time of exercise, the average of the closing prices of such security’s sales on the principal securities exchanges on which such security may at the time be listed, or, if there has been no sales
on any such exchange on any day, the average of the highest bid and lowest asked prices on all such exchanges at the end of such day, or, if on any day such security is not so listed, the average of the last sale prices quoted in the Nasdaq System,
or if on any day such security is not quoted in the Nasdaq System, the average of the highest bid and lowest asked prices on such day in the domestic over-the-counter market as reported by the National Quotation Bureau, Incorporated, or any similar
successor organization, in each such case averaged over a period of five (5) days consisting of the day prior to the day as of which “Market Price” is being determined and the five (5) consecutive business days prior to such day.
If at any time such security is not listed on any securities exchange or quoted in the Nasdaq System or the over-the-counter market, the “Market Price” shall
be the fair value thereof as determined in good faith by the Company’s Board of Directors. 
 6. Adjustment of Exercise Price and
Number of Shares. The number of and kind of Shares purchasable upon exercise of this Warrant and the applicable Exercise Price shall be subject to adjustment from time to time following determination thereof as follows: 

6.1. Subdivisions, Combinations and Other Issuances. If the Company shall at any time prior to the expiration of this Warrant
subdivide the Warrant Stock, by split-up or otherwise, or combine the Warrant Stock, or issue additional shares of the Warrant Stock as a dividend, the number of Warrant Stock issuable on the exercise of this Warrant shall forthwith be
proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price
payable for the total number of shares of Warrant Stock purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 6.1 shall become effective at the close of business on the date the subdivision
or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend. 

6.2. Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization, or change in
the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 6.1 above), 

  
 4 

 
then the Company shall make appropriate provision so that the Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable
upon the exercise of this Warrant, the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Shares as were purchasable
by the Holder immediately prior to such reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be
applicable with respect to any shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price
shall remain the same. 
 6.3. Notice of Adjustment. When any adjustment is required to be made in the number or kind of
shares purchasable upon exercise of the Warrant, or in the Exercise Price therefor, the Company shall promptly notify the Holder of such event and of the number of Shares or other securities or property thereafter purchasable upon exercise of this
Warrant. 
 7. Notice of Proposed Transfers. This Warrant is transferable by the Holder hereof subject to compliance with this
Section 7. Prior to any proposed transfer of this Warrant or the Shares (the “Securities”), unless there is in effect a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), covering the proposed transfer, the Holder thereof shall give written notice to the Company of such Holder’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed
transfer in sufficient detail, and shall, if the Company so requests, be accompanied (except in transactions in compliance with Rule 144) by a written opinion of legal counsel, who shall be reasonably satisfactory to the Company, addressed to the
Company and to the effect that the proposed transfer of the Securities may be effected without registration under the Securities Act and any applicable state securities laws, whereupon the Holder of the Securities shall been titled to transfer the
Securities in accordance with the terms of the notice delivered by the Holder to the Company; provided, however, no such registration statement or opinion of counsel shall be necessary for a transfer by a Holder to any affiliate of such Holder, or a
transfer by a Holder which is a partnership to a partner of such partnership or a retired partner, of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner or the transfer by gift, will or
intestate succession of any partner to his spouse or lineal descendants or ancestors, if the transferee agrees in writing to be subject to the terms hereof to the same extent as if such transferee were the original Holder hereunder. Each certificate
evidencing the Securities transferred as above provided shall bear the appropriate restrictive legend set forth above, except that such certificate shall not bear such restrictive legend if in the opinion of counsel for the Company such legend is
not required in order to establish compliance with any provisions of the Securities Act. 
 8. Replacement of Warrants. Upon
receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of the Warrant, and in the case of any such loss, theft or destruction of the Warrant, on delivery of an indemnity agreement or
security reasonably satisfactory in form and amount to the Company, and reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and cancellation of the Warrant if mutilated, the Company will execute and
deliver, in lieu ·thereof, a new Warrant of like tenor. 

  
 5 

 9. Miscellaneous. This Warrant shall be governed by the internal laws of the State
of California, without regard to the conflict of laws provisions thereof. The headings in this Warrant are for purposes of convenience of reference only, and shall not be deemed to constitute a part hereof. The invalidity or unenforceability of any
provision hereof shall in no way affect the validity or enforceability of any other provisions. All notices and other communications from the Company to the holder of this Warrant shall be given in writing and shall be deemed effectively given as
provided in the Purchase Agreement. 
 10. Taxes. The Company shall pay all issue taxes and other governmental charges (but
not including any income taxes of a Holder) that may be imposed in respect of the issuance or delivery of the Shares or any portion thereof. 

11. Amendment. Any term of this Warrant may be amended or modified only in the manner provided in the Purchase Agreement. Any
amendment or waiver effected in accordance with this Section 11 shall be binding upon the Company, each Holder and each transferee of any Note. 

12. Remedies. In the event of any default or threatened default by the Company in the performance of or observance with any of
the terms of this Warrant, it is agreed that remedies at law are not and will not be adequate for the Holder and that such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by an
injunction against a violation of any of the terms hereof or otherwise. 
 [Signatures follow on the next page] 

  
 6 

 IN WITNESS WHEREOF, the undersigned officer of the Company has set his hand as of the date first
above written. 
  

			
	OBALON THERAPEUTICS, INC.
		
	By:	 	  

		 	Andrew Rasdal,
		 	President and Chief Executive OfficerSERIES C-1 WARRANT

 Exhibit 4.4 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR
OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. 
 AMENDED AND RESTATED 

WARRANT TO PURCHASE STOCK 
  

			
	Corporation:	  	OBALON THERAPEUTICS, Inc., a Delaware corporation
	Number of Shares:	  	25,210
	Class of Stock:	  	Series C-1 Preferred
	Issue Date:	  	June 14, 2013
	Initial Exercise Price:	  	$ 3.57 per share
	Amendment Date:	  	October 1, 2014
	Expiration Date:	  	June 14, 2023

 THIS WARRANT CERTIFIES THAT,
for good and valuable consideration, the receipt of which is hereby acknowledged, SQUARE 1 BANK or its assignee (“Holder”) is
entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the “Shares”) of OBALON THERAPEUTICS, INC., (the “Company”) at the initial exercise price per Share
(the “Warrant Price”) all as set forth above and as adjusted pursuant to Article 2 of this warrant, subject to the provisions and upon the terms and conditions set forth in this warrant. This Amended and Restated
Warrant to Purchase Stock (this “Amended and Restated Warrant’) amends and restates the warrant issued on June 14, 2013 (the “Prior Warrant’). The Prior Warrant is superseded and replaced by
this Amended and Restated Warrant in all respects. 
 ARTICLE 1 

EXERCISE 
 1.1. Method
of Exercise. Holder may exercise this warrant by delivering this warrant and a duly executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the
conversion right set forth in Section 1.2, Holder shall also deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased. 

1.2. Conversion Right. In lieu of exercising this warrant as specified in Section 1.1, Holder may from time to time convert
this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this warrant minus the aggregate Warrant Price of such
Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Section 1.4. 

 1.3. Intentionally Omitted. 

1.4. Fair Market Value. If the Shares are traded regularly in a public market, the fair market value of the Shares shall be the
closing price of the Shares (or the closing price of the Company’s stock into which the Shares are convertible) reported for the business day immediately before Holder delivers its Notice of Exercise to the Company. If the Shares are not
regularly traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment. 

1.5. Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this warrant, the Company shall deliver
to Holder certificates for the Shares acquired and, if this warrant has not been fully exercised or converted and has not expired, a new warrant representing the Shares not so acquired. 

1.6. Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, on surrender and cancellation of this warrant,
the Company at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like tenor. 
 1.7. Repurchase on Sale,
Merger, or Consolidation of the Company. 
 1.7.1 “Acquisition.” For the purpose of this warrant,
“Acquisition” means (a) any sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, (b) any sale or disposition of all or substantially all of the capital
stock of the Company, or (c) any reorganization, consolidation, merger or sale of the voting securities of the Company or any other transaction where the holders of the Company’s securities before the transaction beneficially own less than
50% of the outstanding voting securities of the surviving entity after the transaction. 
 1.7.2 Assumption of Warrant. If upon the
closing of any Acquisition the successor entity assumes the obligations of this warrant, then this warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised
portion of this warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price shall be adjusted accordingly. The Company shall use reasonable efforts to cause the surviving
corporation to assume the obligations of this warrant. 
 1.7.3 Nonassumption. If upon the closing of any Acquisition the
successor entity does not assume the obligations of this warrant and Holder has not otherwise exercised this warrant in full, then Holder shall deem this warrant to have been automatically converted pursuant to Section 1.2 and thereafter Holder
shall participate in the Acquisition on the same terms as other holders of the same class of securities of the Company. 
 1.8. Number of
Shares. The Number of Shares for which this warrant shall be exercisable shall be an amount equal to three percent (3.00%) of the principal amount of the Term Loans made by Square 1 Bank to the Company pursuant to that certain Loan and
Security Agreement by and between the Square 1 Bank and the Company dated as of June 14, 2013 (as may be amended from time to time the “Loan Agreement”) divided by the Initial Exercise Price. All terms used in this Section 1.8
but not defined herein shall have the meanings assigned in the Loan Agreement. 

  
 2 

 ARTICLE 2 

ADJUSTMENTS TO THE SHARES 

2.1. Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable in common stock, or other
securities, or subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this warrant, for each Share acquired, Holder shall receive upon conversion thereof, without cost to Holder, the total number and
kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred. 

2.2. Reclassification, Exchange or Substitution. Upon any reclassification, exchange, substitution, or other event that results in
a change of the number and/or class of the securities issuable upon exercise or conversion of this warrant, Holder shall be entitled to receive, upon exercise or conversion of this warrant, the number and kind of securities and property that Holder
would have received for the Shares if this warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. Such an event shall include any automatic conversion of the outstanding or issuable
securities of the Company of the same class or series as the Shares to common stock pursuant to the terms of the Company’s Certificate of Incorporation upon the closing of a registered public offering of the Company’s common
stock. The Company or its successor shall promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the
adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall
similarly apply to successive reclassifications, exchanges, substitutions, or other events. 
 2.3. Adjustments for Combinations,
Etc. If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are combined or consolidated, by
reclassification or otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased. 
 2.4. Adjustments
for Diluting Issuances. In the event of the issuance (a “Diluting Issuance”) by the Company after the Issue Date of securities at a price per share less than the Warrant Price, then the number of shares of common stock issuable upon
conversion of the Shares shall be adjusted in accordance with those provisions of the Company’s Certificate of Incorporation that apply to Diluting issuances. 

2.5. Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such
adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting
forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 

  
 3 

 2.6. Fractional Shares. No fractional Shares shall be issuable upon exercise or
conversion of the warrant and the Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the warrant, the Company shall eliminate such fractional
share interest by paying Holder the amount computed by multiplying the fractional interest by the fair market value of a full Share. 

ARTICLE 3 

REPRESENTATIONS AND COVENANTS OF THE COMPANY 

3.1. Representations and Warranties. The Company hereby represents and warrants to the Holder as follows: 

(a) The initial Warrant Price referenced on the first page of this warrant is the per share price paid in Company’s most recent
equity financing. 
 (b) All Shares which may be issued upon the exercise of the purchase right represented by this warrant, and all
securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or
under applicable federal and state securities laws. 
 (c) The Company’s capitalization table attached to this warrant is true
and complete as of the Issue Date. 
 3.2. Notice of Certain Events. The Company shall provide Holder with not less than 10 days
prior written notice, including a description of the material facts surrounding, any of the following events: (a) declaration of any dividend or distribution upon its common stock, whether in cash, property, stock, or other securities and
whether or not a regular cash dividend; (b) offering for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; (c) effecting any reclassification or
recapitalization of common stock; or (d) the merger or consolidation with or into any other corporation, or sale, lease, license, or conveyance of all or substantially all of its assets, or liquidation, dissolution or winding up. 

3.3. Information Rights. So long as the Holder holds this warrant and for so long as that certain Second Amended and Restated
Investors’ Rights Agreement by and between the Company and other persons dated as of May 4, 2012, as amended (the “Rights Agreement”), is in force and effect, the Company shall deliver to the Holder (a) within
one hundred eighty (180) days after the end of each fiscal year of the Company, the annual audited (or at other such level as is required by Company’s Board of Directors) financial statements of the Company certified by independent
public accountants of recognized standing and (b) within forty-five (45) days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements. 

  
 4 

 3.4. Registration under Securities Act of 1933, as amended. The Company agrees that
the Shares or, if the Shares are convertible into common stock of the Company, such common stock, shall be “Registrable Securities”, and Holder shall be a “Holder” under and subject to the terms and conditions of the Rights
Agreement. 
 ARTICLE 4 

MISCELLANEOUS 
 4.1.
Term: Exercise upon Expiration. This warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above; provided, however, that if the Company completes its initial public
offering within the three-year period immediately prior to the Expiration Date, the Expiration Date shall automatically be extended until the third anniversary of the effective date of the Company’s initial public offering. If this warrant
has not been exercised prior to the Expiration Date, this warrant shall be deemed to have been automatically exercised on the Expiration Date by “cashless” conversion pursuant to Section 1.2. 

4.2. Legends. This warrant and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any)
shall be imprinted with a legend in substantially the following form as well as any additional legends that the Company and Holder mutually agree upon with respect to such Shares: 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED
EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. 
 4.3. Compliance with Securities Laws on Transfer. This warrant and the Shares issuable
upon exercise of this warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by
the transferor and the transferee. The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder or if there is no material question as to the availability of current information as
referenced in Rule 144(c), Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has compiled with Rule 144(f), and the Company is provided with a copy of Holder’s notice of
proposed sale. 
 4.4. Transfer Procedure. Subject to the provisions of Section 4.3, Holder may transfer all or part of this
warrant or the Shares issuable upon exercise of this warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the portion of the warrant being transferred setting forth the
name, address and taxpayer identification number of the transferee and surrendering this warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable). No surrender or reissuance shall be required if the transfer is to
an affiliate of Holder. 

  
 5 

 4.5. Notices. All notices and other communications from the Company to the Holder, or
vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may be, in writing
by the Company or such Holder from time to time. All notices to the Holder shall be addressed as follows: 
 Square 1 Bank 

Attn: Warrant Administrator 
 406
Blackwell Street, Suite 240 
 Crowe Building 

Durham, NC 27701 
 4.6.
Amendments. This warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

4.7. Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this warrant,
the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

4.8. Governing Law. This warrant shall be governed by and construed in accordance with the laws of the State of California,
without giving effect to its principles regarding conflicts of law. 
 [Balance of Page Intentionally Left Blank]

  
 6 

 
			
	OBALON THERAPEUTICS, INC.
		
	By:	 	 /s/ Andrew Rasdal

		
	Name:	 	 Andrew Rasdal

		
	Title:	 	 Chief Executive Officer

 [Signature Page to Amended and Restated Warrant to Purchase Stock] 

 APPENDIX 1 

NOTICE OF EXERCISE 
 1.
The undersigned hereby elects to purchase              shares of the              stock of OBALON THERAPEUTICS, INC. pursuant to
the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full. 
 1. The undersigned hereby
elects to convert the attached warrant into shares in the manner specified in the Warrant. This conversion is exercised with respect to              of the shares covered by the
warrant. 
 [Strike paragraph that does not apply.] 

2. Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified
below: 
 Square 1 Bank 

Attn: Warrant Administrator 
 406
Blackwell Street, Suite 240 
 Crowe Building 

Durham, NC 27701 
 3. The
undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the resale or distribution thereof except in compliance with applicable securities laws. 

 

	
	SQUARE 1 BANK or Registered Assignee
	
	  

	 (Signature)

	
	  

	(Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]